Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available.
The DUSC reviewed the utilisation of the following PBS listed medicines:
- Atezolizumab for patients with small cell lung cancer
- Durvalumab for patients with non-small-cell lung cancer
- Nivolumab for patients with malignant melanoma
Read DUSC outcome statement
Posted by:
Michael Wonder